Among 159,705 patients in 19 randomized controlled trials, data from 218 asthma patients indicated that SGLT-2 inhibitors were associated with a markedly reduced risk of asthma, with an odds ratio of 0.59 (95% CI: 0.38–0.93). This evidence concerns the gene SLC5A2 and asthma.